Press Release

IMA Action, the new advocacy arm of The Independent Medical Alliance (IMA), formerly FLCCC Alliance, is poised to lead support for public health policy reform as Its mission expands.

FLCCC Alliance co-founders, Dr. Pierre Kory and Dr. Paul Marik, are seeking by motion to join the Association of American Physicians and Surgeons (AAPS) Educational Foundation’s federal lawsuit against the American Board of Internal Medicine (ABIM) and other board-certifying organizations.

Global expansion of FLCCC Fellowship Program now includes 16 countries, representing 30 medical specialties worldwide.

FLCCC Alliance to launch the “Journal of the FLCCC Alliance” featuring research and insights on critical, often under-reported medical topics.

The FLCCC Alliance today announced the addition of 14 new senior fellows to its international fellowship program.

The FLCCC Alliance today announced Lynne Kristensen will step into the newly created senior director, communications role leading global public relations and media strategy for the organization. She will also oversee the FLCCC’s new international Fellowship Program. As the newest member of the executive leadership team, Kristensen brings more than two decades of experience building and leading mission-driven brand strategy and impact communications.  She will spearhead strategic communication initiatives for the organization’s expanding mission in parallel with developing a comprehensive PR strategy for the international Fellowship Program, which is slated to announce senior fellows across fifteen countries and four continents in the coming days.

The FLCCC Alliance today announced its launch of an expansive fellowship program designed to unify and amplify the powerful voices and scholarship of physicians, scientists and other leading health providers and researchers on the global stage. The FLCCC’s senior fellows are among a larger group of professionals who have taken highly public positions to defend the humanitarian values and medical integrity that are central to the Honest Medicine movement. 

The FLCCC Alliance announced today that Dr. Joseph Varon, one of the original co-founders of the organization, has been named president and chief medical officer; he has also been appointed to the board of directors. A globally recognized front line physician and highly published scientist, Dr. Varon is fluent in seven languages and is also the founder of multiple businesses, possessing outstanding organizational leadership skills that the FLCCC requires to execute the strategic plan formulated last fall to significantly expand its breadth of focus, reach, and global impact.

The source of a series of false allegations often recited in media stories has publicly acknowledged her error and apologized for questioning the integrity of the FLCCC Alliance and founding members Paul E. Marik, M.D., FCCM, FCCP, chairman and chief science officer, and Pierre Kory, MD, MPA, president and chief medical officer.

UPDATE March 2025, For more information on the cancer study please contact Rebuildmedicine.com

“We hope that our research will bring attention to often overlooked methods for preventing and treating cancer as well as managing the symptoms from conventional treatment,” said Paul E. Marik, M.D., FCCM, FCCP, co-author of the study and chief scientific officer of the FLCCC.

“What ABIM is doing is basically telling doctors that we need to take our orders from bureaucrats in Washington and certain medical journals instead of making treatment decisions based on our training and expertise,” said Pierre Kory, MD

The FLCCC is grateful for the passage of House Bill 73 (HB73) that passed the Ohio House of Representatives yesterday with bipartisan support. The bill will now go to the Ohio Senate for deliberations and will hopefully be signed into law by Governor DeWine soon.

The source of the false complaint that triggered the nearly year-long investigation into research supporting the use of intravenous Vitamin C to treat medical sepsis has publicly acknowledged his error and expressed regret for questioning the integrity of the study’s lead author, Dr. Paul E. Marik.

Pierre Kory, M.D., president and chief medical officer of the FLCCC, will testify in the Arizona State Senate tomorrow as part of a two-day hearing, joining a delegation of physicians, scientists, and legal experts.

The first-of-its-kind research recognizes that large numbers of people worldwide have been affected by the two conditions and need non-invasive, integrative therapies that can be scaled.

Paul Marik, M.D., co-founder and chief scientific officer of the FLCCC, will testify today to the Health Provider Services Committee of the Ohio State House in support of HB 73, a bill that, if passed into law, will protect doctors and healthcare professionals from unwarranted policies that prevent patient access to repurposed medications.

After an extensive reevaluation, the CHEST Journal reaffirms Dr. Marik’s peer-reviewed publication supporting the use of intravenous Vitamin C to treat medical sepsis in the hospital.

WASHINGTON, D.C. – Pierre Kory, M.D., M.P.A., president and chief medical officer of the FLCCC, testified today to the Health and Government Operations Committee of the Maryland State Assembly in support of HB 699, a bill that, if passed into law, will end the requirement that state government and university employees as well as state university students show proof of COVID-19 vaccination to have a job or attend school.

The FLCCC filed its amicus brief yesterday in support of the lawsuit against the U.S. Department of Health and Human Services (DHHS) for the agency’s campaign against prescribing ivermectin that denied countless patients access to a safe and potentially lifesaving treatment for COVID-19.

FLCCC Files Amicus Brief in Gahl v. Aurora Health

A strictly controlled study of over 88,000 people showed a direct relationship between the dose of ivermectin and the level of protection against the SARS-CoV-2 virus.

Dr. Fauci’s career is a clear demonstration of what many fear most from our government: ego-driven technocrats pushing a failing, evidence-free political agenda on the country with no transparency or accountability.

Paul E. Marik, M.D. response to the American Board of Internal Medicine (“ABIM” or “Board”) letter of May 26, 2022  raising concerns that Dr. Marik is spreading medical misinformation regarding the prevention and treatment of COVID-19.

The response sent on behalf of Pierre Kory, MD to the American Board of Internal Medicine (ABIM) letter of May 26, 2022 raising concerns that Dr. Kory is spreading medical misinformation regarding the prevention and treatment of COVID-19.

FLCCC mourns the loss of Dr. Vladimir Zelenko, fierce advocate for early COVID treatment The entire team at FLCCC is saddened to hear of the loss of a great friend and fellow supporter of early treatment for COVID-19. We extend our deepest condolences and sympathies to the Zelenko family and pray they find the strength to see them through this difficult time. “Dr. Zelenko stepped up and fought for access to early treatment when few others did,” said Dr. Pierre Kory, President and Chief Medical Officer of FLCCC. “He had a huge impact, and his loss will be felt by many.”

ACTIV-6 severely limited the use of ivermectin, administering a dose below what is known to be effective on the variants at the time and received too late (6 days on average) after the onset of symptoms. Despite these obvious shortfalls, there was a statistically significant, albeit modest, impact on time to clinical recovery for patients using ivermectin to treat COVID-19. T

Dr. Paul Marik, Dr. Mary Talley Bowden and Dr. Robert L. Apter challenge the FDA regarding ivermectin as a COVID treatment.

The FLCCC is pleased with the recent legislative developments in New Hampshire that will allow over the counter (OTC) access to ivermectin.

Treating early is imperative. Yet the TOGETHER trial studied patients where they started treatment up to eight days after the onset of symptoms.

On March 11, the Virginia House of Delegates passed a resolution by unanimous vote that commends Paul Marik, MD, one of the world’s leading critical care physicians, for his distinguished career and courageous life-saving work during the COVID-19 pandemic. HR 228 recognizes Dr. Marik for “his courageous treatment of critically ill COVID-19 patients and his philanthropic efforts to share his effective treatment protocols with physicians around the world.”

“The lawsuit was about doctors, to have the ability to honor their Hippocratic Oath, to follow evidence-based medicine, and to treat patients the best we know how,” said Dr. Marik. “I plan to continue advocating for doctors and patients as I focus my attention on my work with the FLCCC and other academic interests.”

 FLCCC Founder Dr. Paul Marik sues the hospital he works at for the right to treat COVID patients with safe, effective treatments.

The hearing set for Thursday, November 18, could lead to the reinstatement of several treatments that are currently banned by the Sentara Healthcare System.

Smith, the 51-year-old father of 3 whose wife went to court to compel a Cincinnati hospital to give him IVM as a last resort, received 13 days of ivermectin and showed improvement, until the court order was rescinded and the hospital refused to provide more IVM.

We commend the efforts of the Island of Grenada in managing to limit the spread of Covid-19 and we understand that the government is anxious to keep cases at a minimum.

We commend the efforts of the Republic of Trinidad and Tobago in mitigating the suffering of Trinidadians and Tobagonians at this trying time. FLCCC Alliance and BiRD Group Joint Statement for Trinidad and Tobago

A reexamination of the data without the earlier research continues to prove that ivermectin is effective in preventing and treating COVID-19

Joint Statement of the FLCCC & the BiRD Group on the Unethical and Questionable Methods of the Upcoming PRINCIPLE Trial.

Transcript of Dr. Kory's video message on the U.S. Deal to Give $1.2 Billion Taxpayer Dollars to Merck Instead of distributing safe, effective, inexpensive ivermectin

Read the joint statement for Namibia from the FLCCC Alliance and the BiRD Group.

The joint statement for Jamaica from the FLCCC Alliance and the BiRD Group on ivermectin as a COVID-19 treatment.

The study, published in the American Journal of Therapeutics, used the highest scientific standards to evaluate the efficacy of ivermectin and found that “large reductions in COVID-19 deaths are possible with the use of ivermectin.”

Read the Joint Statement for Sri Lanka from FLCCC Alliance and the BiRD Group.

Click here to read the Letter To Indonesia from the FLCCC Alliance.

Read the Joint Statement for Afghanistan from the FLCCC Alliance and the BiRD Group regarding ivermectin.

Awareness of ivermectin’s efficacy and its adoption by physicians worldwide to successfully treat COVID-19 have grown exponentially over the past several months.

We commend the tremendous efforts of the Indian central government, state governments, media personnel, doctors, nursing staff, police personnel, paramedical staff and other organisations in mitigating the suffering of Indians at this time.

We appreciate the interest from the Washington Post in the use of ivermectin as a safe and effective preventative and treatment for COVID-19.

The World Health Organization and National Institutes of Health now have all the data they need to recommend ivermectin to prevent and treat COVID-19. And those who want to end this pandemic now, for all countries rich and poor, should welcome that move.

Despite the rapidly increasing and diverse amounts of medical evidence supporting ivermectin as a life-saving therapy in COVID, multiple national and international health agencies – including but not limited to the World Health Organization, the European Medicines Agency, and the regulatory health agencies of all of North America and Europe – have continued to issue negative recommendations against use of ivermectin in COVID-19.

The Front Line COVID-19 Critical Care Alliance (FLCCC), a group of highly published, world-renowned critical care physicians and scholars, today praised the recent updated guidance from the All India Institute of Medical Science (AIIMS) to include ivermectin in its guidelines for the treatment of COVID-19.

WHO ignores significant data, including several large clinical trials, while claiming insufficient evidence to recommend the use of ivermectin to prevent and treat COVID-19

Scientists and physicians from the U.S., U.K., E.U., South America, and Israel gathered to discuss the latest data on how ivermectin has reduced positive COVID-19 cases in major cities across the world, ivermectin's role in the early treatment of COVID-19, and why ivermectin needs to be adopted as safe and effective prevention and treatment of COVID-19.

FLCCC Alliance Applauds International Group of Medical Experts’ Recognition of Ivermectin as a Safe and Effective Treatment for COVID-19

The FLCCC Alliance is troubled by the recently updated consumer guidance on Ivermectin from the FDA. The guidance from the FDA is misleading and has the potential to raise unwarranted concern over an important drug in the prevention and treatment of COVID-19.

Merck’s assessments of ivermectin’s efficacy in COVID-19 are in striking contrast with the findings reported by multiple expert group’s systematic reviews from across the globe.

On January 6, 2021, Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data on ivermectin before the National Institutes of Health (NIH) Treatment Guidelines Panel.

FLCCC Alliance Invited to the National Institutes of Health (NIH) COVID-19 Treatment Guidelines Panel to Present Latest Data on Ivermectin FLCCC Urges Expedited Review of Current Data and an Updated NIH Guidance

FLCCC Alliance calls on national health authorities to immediately review medical evidence showing the efficacy of ivermectin for the prevention of COVID-19 and as an early outpatient treatment.